FDA Lifts Clinical Hold on Editas Gene Editing Therapy in Sickle Cell Disease

Massachusetts-based Editas Medicine announced that the FDA has removed a partial clinical hold on its trial of EDIT-301 (AsCas12a), its experimental gene treatment for severe sickle cell disease.
Source: Drug Industry Daily